Implant-associated local drug delivery systems based on biodegradable polymers: Customized designs for different medical applications

Biomedizinische Technik

Volumn 58, Issue 5, 2013, Pages 417-427

  Sternberg, Katrin ^a   Petersen, Svea ^a,b   Grabow, Niels ^a   Senz, Volkmar ^a   Schwabedissen, Henriette Meyerzu ^a,c   Kroemer, Heyo K ^a,c   Schmitz, Klaus Peter ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b Niels Grabow Volkmar Senz and Klaus Peter Rostock   (Germany)

^c UNIVERSITY MEDICINE GREIFSWALD   (Germany)

Author keywords

Biodegradable polymers; Implant coating; Local drug delivery; Surface functionalization

Indexed keywords

BIODEGRADABLE POLYMERS; BLENDING; DRUG DELIVERY; LOADING; MEDICAL APPLICATIONS; SYSTEMS ANALYSIS;

DIFFUSION-CONTROLLED; DRUG-ELUTING STENTS; IN-STENT RESTENOSIS; LOCAL DRUG DELIVERY; POLYMERIC DRUG CARRIERS; SEMI-CRYSTALLINE POLYMER; SURFACE FUNCTIONALIZATION; UNDESIRABLE EFFECTS;

PLASTIC COATINGS;

DELAYED RELEASE FORMULATION; POLYMER;

ADMINISTRATION AND DOSAGE; BIODEGRADABLE IMPLANT; CHEMISTRY; DELAYED RELEASE FORMULATION; DIFFUSION; DRUG DESIGN; DRUG ELUTING STENT; MATERIALS TESTING; PROSTHESIS; SYNTHESIS; REVIEW;

ABSORBABLE IMPLANTS; DELAYED-ACTION PREPARATIONS; DIFFUSION; DRUG DESIGN; DRUG-ELUTING STENTS; MATERIALS TESTING; POLYMERS; PROSTHESIS DESIGN;

EID: 84897067054     PISSN: 00135585     EISSN: None     Source Type: Journal    
DOI: 10.1515/bmt-2012-0049     Document Type: Review

References (59)

1. Acharya G, Park K. Mechanisms of controlled drug release from drug-eluting stents. Adv Drug Deliv Rev 2006; 58: 387-401.
2. Alexis F. Factors affecting the degradation and drug-release mechanism of poly(lactic acid) and poly[(lactic acid)-co-(glycolic acid)]. Polym Int 2005; 54: 36-46.
3. Andreopoulos AG. Plasticization of biodegradable polymers for use in controlled release. Clin Mater 1994; 15: 89-92.
4. Banai S, Chorny M, Gertz SD, et al. Locally delivered nanoencapsulated Tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. Biomaterials 2005; 26: 451-461.
5. Bangham AD. Liposomes: the Babraham connection. Chem Phys Lipids 1993; 64: 275-285.
6. Bhargava B, Reddy NK, Karthikeyan G, et al. A novel paclitaxel-eluting porous carbon-carbon nanoparticle coated, nonpolymeric cobalt-chromium stent: evaluation in a porcine model. Catheter Cardiovasc Interv 2006; 67: 698-702.
7. Bohl A, Rohm HW, Ceschi P, et al. Development of a specially tailored local drug delivery system for the prevention of fibrosis after insertion of cochlear implants into the inner ear. J Mater Sci Mater Med 2012; 23: 2151-2162.
8. Bünger CM, Grabow N, Kröger C, et al. Iliac anastomotic stenting with a sirolimus-eluting biodegradable poly-L-lactide stent: a preliminary study after 6 weeks. J Endovasc Ther 2006; 13: 630-639.
9. Bünger CM, Grabow N, Sternberg K, et al. Sirolimus-eluting biodegradable poly-L-lactide stent for peripheral vascular application: a preliminary study in porcine carotid arteries. J Surg Res 2007; 139: 77-82.
10. Cen D, Gonzalez RI, Buckmeier JA, Kahlon RS, Tohidian NB, Meyskens FL Jr. Disulfiram induces apoptosis in human melanoma cells: a redox-related process. Mol Cancer Ther 2002; 1: 197-204.
11. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331: 496-501.
12. Freier T, Kunze C, Nischan C, et al. In vitro and in vivo degradation studies for development of a biodegradable patch based on poly(3- hydroxybutyrate). Biomaterials 2002; 23: 2649-2657.
13. Garg S, Serruys PW. Coronary stents: current status. J Am Coll Cardiol 2010; 56: S1-S42.
14. Garg S, Serruys PW. Coronary stents: looking forward. J Am Coll Cardiol 2010; 56: S43-S78.
15. Goddard JM, Hotchkiss JH. Polymer surface modification for the attachment of bioactive compounds. Prog Polym Sci 2007; 32: 698-725.
16. Grabow N, Martin DP, Schmitz K-P, Sternberg K. Absorbable polymer stent technologies for vascular regeneration. J Chem Technol Biotechnol 2010; 85: 744-751.
17. Grabow N, Schlun M, Sternberg K, Hakansson N, Kramer S, Schmitz K-P. Mechanical properties of laser cut poly(L-lactide) micro-specimens: implications for stent design, manufacture, and sterilization. J Biomech Eng 2005; 127: 25-31.
18. Grüntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979; 301: 61-68.
19. Gümüşderelioglu M, Deniz G. Sustained release of mitomycin-C from poly(DL-lactide)/poly(DL-lactide-co-glycolide) films. J Biomater Sci Polym Ed 2000; 11: 1039-1050.
20. Hargunani CA, Kempton JB, DeGagne JM, Trune DR. Intratympanic injection of dexamethasone: time course of inner ear distribution and conversion to its active form. Otol Neurotol 2006; 27: 564-569.
21. Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 2008; 60: 876-885.
22. Jedlinski Z, Kowalczuk M, Glowkowski W, Grobelny J, Szwarc M. Novel polymerization of b-butyrolactone initiated by potassium naphthalenide in the presence of a crown ether or a cryptand. Macromolecules 1991; 24: 349-352.
23. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
24. Kim SH, Jeong JH, Chun KW, Park TG. Target-specific cellular uptake of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)-folate conjugate. Langmuir 2005; 21: 8852-8857.
25. Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009; 119: 3198-3206.
26. Kober T, König I, Weber M, Kojda G. Diethyldithiocarbamate inhibits the catalytic activity of xanthine oxidase. FEBS Lett 2003; 551: 99-103.
27. Lanzer P, Sternberg K, Schmitz KP, Kolodgie F, Nakazawa G, Virmani R. Drug-eluting coronary stent very late thrombosis revisited. Herz 2008; 33: 334-342.
28. Lendlein A. Polymere als Implantatwerkstoffe. Chem Unserer Zeit 1999; 33: 279-295.
29. Lipsky JJ, Shen ML, Naylor S. Overview -in vitro inhibition of aldehyde dehydrogenase by disulfiram and metabolites. Chem Biol Interact 2001; 130-132: 81-91.
30. Löbler M, Sternberg K, Stachs O, et al. Polymers and drugs suitable for the development of a drug delivery drainage system in glaucoma surgery. J Biomed Mater Res B Appl Biomater 2011; 97: 388-395.
31. Luderer F, Begerow I, Schmidt W, et al Enhanced visualization of biodegradable polymeric vascular scaffolds by incorporation of gold, silver and magnetite nanoparticles. J Biomater Appl 2012 [Epub ahead of print].
32. Luderer F, Löbler M, Rohm HW, et al. Biodegradable sirolimusloaded poly(lactide) nanoparticles as drug delivery system for the prevention of in-stent restenosis in coronary stent application. J Biomater Appl 2011; 25: 851-875.
33. Marks AR. Cellular functions of immunophilins. Physiol Rev 1996; 76: 631-649.
34. Martin DP, Williams SF. Medical applications of poly-4-hydroxybutyrate: a strong flexible absorbable biomaterial. Biochem Eng J 2003; 16: 97-105.
35. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995; 76: 412-417.
36. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387-6392.
37. Meiser BM, Morris RE, Billingham ME. Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. Lancet 1991; 338: 1297-1298.
38. Minelli C, Lowe SB, Stevens MM. Engineering nanocomposite materials for cancer therapy. Small 2010; 6: 2336-2357.
39. Miyata T, Asami N, Uragami T. A reversibly antigen-responsive hydrogel. Nature 1999; 399: 766-769.
40. Miyata T, Asami N, Uragami T. Structural design of stimuliresponsive bioconjugated hydrogels that respond to a target antigen. J Polym Sci B Polymer Phys 2009; 47: 2144-2157.
41. Moellering D, McAndrew J, Jo H, Darley-Usmar VM. Effects of pyrrolidine dithiocarbamate on endothelial cells: protection against oxidative stress. Free Radic Biol Med 1999; 26: 1138-1145.
42. Mohacsi PJ, Tüller D, Hulliger B, Wijngaard PL. Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transplant 1997; 16: 484-492.
43. Moon JI, Kim YS, Kim MS, et al. Effect of cyclosporine, mycophenolic acid, and rapamycin on the proliferation of rat aortic vascular smooth muscle cells: in vitro study. Transplant Proc 2000; 32: 2026-2027.
44. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
45. Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006; 47: 175-181.
46. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996; 98: 2277-2283.
47. Regar E, Sianos G, Serruys PW. Stent development and local drug delivery. Br Med Bull 2001; 59: 227-248.
48. Schultz D, Skamarauskas JT, Law N, Mitchinson MJ, Hunt JV. The inhibition of foam cell formation by sodium diethyldithiocarbamate. Free Radic Res 1995; 23: 259-271.
49. Serruys PW, De Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331: 489-495.
50. Shian S-G, Kao Y-R, Wu FY-H, Wu C-W. Inhibition of invasion and angiogenesis by zinc-chelating agent disulfiram. Mol Pharmacol 2003; 64: 1076-1084.
51. Sternberg K, Kramer S, Nischan C, et al. In vitro study of drug-eluting stent coatings based on poly(l-lactide) incorporating cyclosporine A -drug release, polymer degradation and mechanical integrity. J Mater Sci Mater Med 2007; 18: 1423-1432.
52. Sternberg K, Petersen S, Grabow N, et al. Implant-associated local drug delivery systems for different medical applications. Biomed Tech (Berl) 2012; 57(Suppl. 1): 393-396.
53. Stoltenberg RL, Geraghty J, Steele DM, Kennedy E, Hullett DA, Sollinger HW. Inhibition of intimal hyperplasia in rat aortic allografts with cyclosporine. Transplantation 1995; 60: 993-998.
54. Taylor RD, Maners AW, Salari H, Baker M, Walker EM Jr. Disulfiram as a radiation modifier. Ann Clin Lab Sci 1986; 16: 443-449.
55. Van de Water TR, Dinh CT, Vivero R, et al. Mechanisms of hearing loss from trauma and inflammation: otoprotective therapies from the laboratory to the clinic. Acta Otolaryngol 2010; 130: 308-311.
56. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012; 63: 185-198.
57. Wang W, McLeod HL, Cassidy J. Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer 2003; 104: 504-511.
58. Wulf K, Teske M, Löbler M, Luderer F, Schmitz K-P, Sternberg K. Surface functionalization of poly(-caprolactone) improves its biocompatibility as scaffold material for bioartificial vessel prostheses. J Biomed Mater Res B Appl Biomater 2011; 98B: 89-100.
59. Yilmaz B, Cetin M, Palabiyik SS, Asci A. HPLC method for determination of disulfiram in pharmaceutical preparations. Alfa Univ Int J Chem 2010; 1: 79-86.